Knight Therapeutics signs Latin America deal for Kyowa Kirin's Poteligeo

Knight Therapeutics has entered into an exclusive distribution agreement with Kyowa Kirin International to bring mogamulizumab, marketed as Poteligeo, to four major Latin American markets. Under the deal, the Montreal-listed company will be responsible for obtaining regulatory approvals and commercialising the drug in Brazil, Mexico, Colombia and Argentina, expanding access to an already approved therapy for a rare and debilitating form of lymphoma.

Mogamulizumab is a humanised monoclonal antibody that targets chemokine receptor 4 (CCR4), a protein expressed on malignant T cells in cutaneous T-cell lymphoma (CTCL). The drug is already approved in the United States and Europe for adult patients with relapsed or refractory mycosis fungoides or Sézary syndrome, the two most prevalent subtypes of CTCL, after at least one prior systemic therapy.

The science and the data

The approvals in established markets rest on the MAVORIC Phase 3 trial, which randomised 372 patients to mogamulizumab or vorinostat. Mogamulizumab produced a median progression-free survival of 7.7 months compared with 3.1 months for vorinostat, yielding a hazard ratio of 0.53 (95% CI: 0.41–0.69; p less than 0.001). The confirmed overall response rate was 28% versus 5% for the comparator. The most common adverse events included rash, infusion-related reactions and upper respiratory tract infections, and clinicians will weigh these against the meaningful PFS benefit when considering treatment sequencing.

CTCL is classified as a rare non-Hodgkin lymphoma that can affect the skin, blood, lymph nodes and internal organs. Diagnosis is frequently delayed because early-stage lesions can mimic benign dermatological conditions. Epidemiological data for the region are limited, but incidence in Latin America is believed to be broadly comparable to the United States, where mycosis fungoides is reported at approximately 5.42 per million annually and Sézary syndrome at 0.21 per million.

Samira Sakhia, president and chief executive of Knight Therapeutics, said the product "addresses a significant unmet medical need and will provide patients across our key Latin American markets with access to a much-needed new therapeutic option."

Market context and competitive landscape

For Knight, the agreement adds to an existing haemato-oncology portfolio built through a series of in-licensing deals across Latin America, where the company operates via subsidiaries including United Medical, Biotoscana Farma and Laboratorio LKM. Securing distribution rights ahead of regulatory filings in four markets simultaneously is an ambitious regulatory workload, and timelines will depend on the speed of each country's review pathway, notably Anvisa in Brazil and COFEPRIS in Mexico, both of which have been modernising their oncology accelerated review frameworks in recent years.

The CTCL treatment landscape in approved markets features a small number of systemic agents, including vorinostat, romidepsin and bexarotene, as well as brentuximab vedotin for select CD30-positive patients. Mogamulizumab's first-in-class CCR4 mechanism differentiates it from these options, though uptake in Latin America will depend on reimbursement negotiations, physician awareness and the limited epidemiological infrastructure for rare-disease diagnosis in the region. Knight's experience navigating those hurdles in prior launches across its portfolio gives it a practical advantage over a new market entrant, but investors should expect a multi-year commercialisation ramp before meaningful revenue contribution.